Table 3.
Demographic characteristics and data on vitamin D supplementation, omega-3 PUFA supplementation, serum vitamin D levels and plasma AA/EPA ratio of islet transplant recipients with long-term allograft function who completed last follow-up visit (2019) at Diabetes Research Institute (Clinical Cell Transplant Program, University of Miami Miller School of Medicine). Abbreviations: 25(OH)D, 25-hydroxyvitamin D; AA, arachidonic acid; BMI, body mass index; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; IU, international units; PUFA, polyunsaturated fatty acid; SD, standard deviation.
| n | 17 |
|---|---|
| Gender | 12 females, 5 males |
| Mean age ± SD (years) | 55.2 ± 4.9 |
| Mean BMI ± SD (kg/m2) | 22.1 ± 0.4 |
| Mean duration of graft function ± SD (years) | 11.1 ± 8.4 |
| Mean serum 25(OH)D levels ± SD (ng/mL) | 51.0 ±7.0 |
| Mean plasma AA/EPA ratio ± SD | 31.3 ± 12.3 |
| Vitamin D users * | n = 15 |
| Mean total daily dose of vitamin D (IU/day) | 1626 IU |
| Mean daily dose of vitamin D (IU/kg/day) | 28.4 |
| Omega-3 PUFA users (EPA and DHA) ** | n = 5 *** |
| Mean total daily dose of omega-3 PUFAs (mg/day) | 2000 |
| Mean daily dose of omega-3 PUFAs (mg/kg/day) | 33.5 |
| Mean plasma AA/EPA ratio values ± SD among omega-3 PUFA users | 3.7 ± 1.7 |
* All subjects were on cholecalciferol (vitamin D3); ** Omega-3 PUFA supplementation consisted of an EPA/DHA ratio of 2:1; *** 4 out of 5 omega-3 PUFA users were also on vitamin D supplementation (vitamin D and omega-3 PUFA co-supplementation).